Obermatt

Divi's Laboratories

NSI:DIVISLAB · INE361B01024
Life Sciences Tools & ServicesLarge

360

52
EV / EBIT5
Price / Owner Earnings4
Owner Earnings Yield43
Dividend Yield47
Price/Sales1
EV / Gross Profit5
Price/Book10
Return on Capital89
Cash Return on Capital55
Return on Equity82
EBIT Margin91
Gross Profitability83
Cash Conversion17
Owner Earnings Margin51
Sales growth77
Profit Growth75
Long-Term EPS Growth78
Reinvestment7
Price momentum55
Debt load97
Refinancing22
Debt Payback100
Liquidity91
Analyst ratings24
Opinion Changes37
Price Target Upside23
Market mood65
Value Creation13/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Divi's Laboratories clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryIndia
IndustryLife Sciences Tools & Services
SizeLarge
TypePublic Company
ExchangeNSEI
Founded1990
Employees1,759
ISININE361B01024
Last UpdateApr 2, 2026
Index & Theme
Animal FeedNutraceuticalManufacturingPharmaceutical

Description

Analysis

Hope premium

Divi's Laboratories Limited carries what we call a hope premium: an average business trading at an ambitious price. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is expensive. You pay 317.8× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 45% yearly growth; analysts expect 19%. The market is pricing in far more than analysts expect: heroic expectations.

The trajectory is solid and the balance sheet is sturdy. The company scores 13/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
30
2023202420252026

All-time high

63

Feb 2024

All-time low

15

Jul 2023

Average rank

35

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
1
1
5
3
Price/Earnings
7
5
12
22
Price/Book
10
14
28
20
Dividend Yield
47
34
42
34
Value (overall)
7
5
19
13

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Divi's Laboratories with its peers
Dr. Reddy's
NSI:DRREDDY
29
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Ipca Laboratories
NSI:IPCALAB
58
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
PI Industries
NSI:PIIND
63
CountryIndia
IndustryChemicals
SizeLarge
Full Stock Analysis →
Global Green Chemicals
SET:GGC
24
CountryThailand
IndustryChemicals
SizeSmall
Full Stock Analysis →
Granules India
NSI:GRANULES
65
CountryIndia
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Alkem Laboratories
NSI:ALKEM
47
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →